Insilico Medicine (3696.HK), a clinical-stage biopharmaceutical company leveraging generative artificial intelligence to accelerate drug discovery, and MobiDrop, a single-cell multi-omics technology company specializing in the large-scale generation of high-quality, AI-ready life science data, today announced a strategic partnership. Bringing together complementary strengths at the forefront of single-cell technology and AI-driven drug discovery, the two companies will collaborate on the generation, integration, and application of high-quality, traceable, AI-ready single-cell multi-omics data. Multi-omics datasets generated at scale by MobiDrop will be systematically integrated into the data infrastructure supporting Insilico Medicine’s Pharma.AI platform, providing data for the training, validation, and continuous refinement of its core generative biology platform, PandaOmics, as well as its recently released multi-agent-driven Virtual Aging Cell (VAC) platform.

Generative AI is redefining the pace and economics of drug discovery. Early-stage drug discovery, which traditionally takes approximately 2.5 to 4 years, can now be accelerated to an average of 12 to 18 months through AI-driven approaches. At the same time, the industry is increasingly recognizing that as algorithms and computing resources become more widely accessible, high-quality, traceable experimental data derived from real biological systems is emerging as a critical bottleneck -- and a key source of competitive advantage -- in AI-driven drug discovery. Publicly available databases have been extensively mined for model training and are becoming increasingly saturated. To move AI models beyond prediction toward experimental validation, and from content generation toward truly closed-loop discovery, a continuous supply of novel, multimodal wet-lab data is essential.

Under the agreement, the two companies will establish a long-term, non-exclusive strategic collaboration spanning key applications including target validation, disease mechanism research, biomarker discovery, and indication selection. Insilico Medicine will identify real-world R&D needs from its internal pipeline to serve as use cases, while MobiDrop will leverage its proprietary single-cell technologies, automated experimental platforms, and intelligent data analysis capabilities to generate and deliver high-quality, AI-ready experimental datasets at scale. Data generated through joint projects will be fed back into Insilico Medicine’s platform for model evaluation and refinement, establishing a continuous feedback loop of data generation, model iteration, accelerated R&D, and novel data generation.

In August 2026, Insilico Medicine also released an interactive preview of its VAC platform, powered by a “Multi-Agent Swarms”. The platform introduces biological age as a core conditioning variable and enables coordinated reasoning across six biological scales, spanning molecules, cells, tissues, and organismal populations, to simulate dynamic biological systems across healthy and disease states. As part of the strategic collaboration, the two companies will jointly develop training and benchmarking datasets for same-cell multimodal models, providing the VAC platform with real-world, traceable wet-lab reference data. This collaboration aims to advance AI-powered virtual cells from “understanding biology” toward “intervening in cell fate,” enabling a scalable closed-loop framework that integrates in silico modeling with wet-lab experimentation at single-cell resolution.

Dr. Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, said:

“We believe that the ultimate potential of AI is fundamentally determined by the quality and depth of the data on which it is built. While Insilico Medicine has accumulated extensive proprietary R&D data through its in-house automated laboratories, every advance in AI -- from target validation to virtual cells -- requires increasingly robust, real-world, and traceable biological evidence. MobiDrop is a leading player in China’s single-cell technology ecosystem, integrating microfluidics, biochemistry, bioinformatics, and quality control into an end-to-end data-generation platform. This collaboration enables us to incorporate high-quality multi-omics data at scale through a systematic and highly engineered approach. By accelerating model training, validation, and iteration, we aim to advance AI-driven drug discovery beyond simply ‘assisting drug discovery’ toward a deeper understanding of dynamic biological systems.”

Dr. Hao Pei, Founder and General Manager of MobiDrop, said:

“At MobiDrop, we share Insilico Medicine’s conviction that the next phase of AI for Science must be built on large-scale, high-quality, and traceable data generated from real biological systems. Our mission is to leverage microfluidics and single-cell technologies to make biological systems measurable with greater accuracy, comprehensiveness, speed, and affordability, and to transform these measurements into a data language that AI can learn from, validate, and ultimately act upon. Our strategic collaboration with Insilico Medicine helps bridge the gap between ‘screening millions of molecules’ and ‘experimenting on millions of real cells’. We look forward to working closely with the Insilico Medicine team over the long term to transform the concept of the ‘cellular digital twin’ from an emerging concept into a measurable, reproducible, and scalable capability for the life sciences industry.”

MobiDrop has developed an industry-leading portfolio of single-cell multi-omics products covering a broad range of species, including animals, plants, and microorganisms; diverse sample types, including fresh, cryopreserved, and FFPE samples; and major omics modalities, including transcriptomics, epigenomics, and genomics. The company has developed proprietary technologies and intellectual property across its technology platforms. As AI models for the life sciences continue to evolve, MobiDrop will further advance next-generation technologies, including ultra-high-throughput and paired multi-omics approaches, while strengthening its end-to-end infrastructure spanning life science data generation, AI training, and model validation. These efforts will provide virtual cell technologies and AI-driven life science research with a richer, higher-quality, and more scalable data foundation.

About Insilico Medicine

Insilico Medicine is a global biotechnology company pioneering the integration of artificial intelligence and automation to accelerate drug discovery and advance innovation in the life sciences, with the goal of enabling people to live longer and healthier lives. On December 30, 2025, the company was listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 03696.HK.

Powered by its proprietary Pharma.AI platform and advanced automated biology laboratories, Insilico Medicine is developing innovative drug solutions for areas of significant unmet medical need, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. The company is also expanding the application of Pharma.AI across a diverse range of fields, including advanced materials, agriculture, nutritional products, and veterinary medicine.

For more information, please visit www.insilico.com.

About MobiDrop

Founded in Boston, Massachusetts, and with operations in Jiaxing, Zhejiang, China, MobiDrop is a life science data infrastructure company focused on generating high-quality biological data for AI for Science. Through automated perturbation experiments, multimodal measurements, and industrial-grade quality control systems, the company is developing the capabilities required to generate high-quality life science data at scale. MobiDrop’s proprietary MobiNova®-100 single-cell sequencing system can capture 100,000 cells in as little as six minutes, with a capture efficiency of up to 70% and a multiplet rate of ≤ 5%, delivering core performance at an internationally leading level. Its MobiNova®-M1 microbial single-cell genome sequencing library preparation system is the first of its kind globally, and related research findings have been published in Science. MobiDrop operates a global headquarters in Jiaxing, China, an innovation center in Shanghai, China, and a global innovation and business center in Cambridge, Massachusetts, USA. The company maintains deep collaborations with leading research institutions, pharmaceutical companies, and top-tier hospitals in China and around the world.